Add a few U.S. attorneys to the long list of folks looking into what happened with that failed trial of Vytorin, the cholesterol drug from Merck and Schering-Plough.
There was a flurry of action in the early months of the year, as the company reported that the drug failed to show a benefit over a generic [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment